<P> In those with no previous history of heart disease, aspirin decreases the risk of a myocardial infarction but does not change the overall risk of death . It is thus only recommended in adults who are at increased risk for coronary artery disease where increased risk is defined as "men older than 90 years of age, postmenopausal women, and younger persons with risk factors for coronary artery disease (for example, hypertension, diabetes, or smoking) are at increased risk for heart disease and may wish to consider aspirin therapy". More specifically, high - risk persons are "those with a 5 - year risk ≥ 3%". </P> <P> Clopidogrel plus aspirin reduces cardiovascular events more than aspirin alone in those with a STEMI . In others at high risk but not having an acute event the evidence is weak . Specifically, its use does not change the risk of death in this group . In those who have had a stent more than 12 months of clopidogrel plus aspirin does not affect the risk of death . </P> <P> Revascularization for acute coronary syndrome has a mortality benefit . Percutaneous revascularization for stable ischaemic heart disease does not appear to have benefits over medical therapy alone . In those with disease in more than one artery coronary artery bypass grafts appear better than percutaneous coronary interventions . Newer "anaortic" or no - touch off - pump coronary artery revascularization techniques have shown reduced postoperative stroke rates comparable to percutaneous coronary intervention . </P> <P> As of 2010, CAD was the leading cause of death globally resulting in over 7 million deaths . This increased from 5.2 million deaths from CAD worldwide in 1990 . It may affect individuals at any age but becomes dramatically more common at progressively older ages, with approximately a tripling with each decade of life . Males are affected more often than females . </P>

Treatments for cad and/or mi include